Cited by 225

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, Albert, Davis, Alan K, Erowid, Fire, Erowid, Earth, Griffiths, Roland R, Johnson, Matthew W·2019·Journal of Psychopharmacology

DOI 10.1177/0269881119845793

Open this paper in CoChat — free account

Abstract

Background: Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims: To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use. Methods: An anonymous online survey of individuals with prior AUD reporting cessation or reduction in alcohol use following psychedelic use in non-clinical settings. Results: 343 respondents, mostly White (89%), males (78%), in the USA (60%) completed the survey. Participants reported seven years of problematic alcohol use on average before the psychedelic experience to which they attributed reduced alcohol consumption, with 72% meeting retrospective criteria for severe AUD. Most reported taking a moderate or high dose of LSD (38%) or psilocybin (36%), followed by significant reduction in alcohol consumption. After the psychedelic experience 83% no longer met AUD criteria. Participants rated their psychedelic experience as highly meaningful and insightful, with 28% endorsing psychedelic-associated changes in life priorities or values as facilitating reduced alcohol misuse. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with a greater reduction in alcohol consumption, controlling for prior alcohol consumption and related distress. Conclusions: Although results cannot demonstrate causality, they suggest that naturalistic psychedelic use may lead to cessation or reduction in problematic alcohol use, supporting further investigation of psychedelic-assisted treatment for AUD.

Integrity signals

Registry

Crossref · 10.1177/0269881119845793

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption‐II
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597 · cited 2×
“This instrument consists of the first three items of the AUDIT (Saunders et al., 1993), and provides a validated measure of alcohol use, with AUDIT-C scores ⩾3 (in women) or ⩾4 (in men) indicating potential misuse (Bush et al., 1998).”
Method
Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III
Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“…depression (Carhart-Harris et al., 2016, 2017; dos Santos et al., 2016; Palhano-Fontes et al., 2019), as well as patients with symptoms of anxiety or depression associated with life-threatening illness (Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016).”
BackgroundSelf-citation
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 2×
“%) in the study sample was high, consistent with data showing significant comorbidity between AUD and mood and anxiety disorders (Grant et al., 2015; Hasin et al., 2018; Lai et al., 2015).”
Result
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citation
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 9×
“…found that both greater overall intensity of drug effects and greater mystical-type effects were highly correlated with subsequent decreases in percentage drinking days and percentage heavy drinking days, decreased craving, and increased alcohol abstinence self-efficacy (Bogenschutz et al., 2015).”
BackgroundInfluential
Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis
Lai, H. M. X., Cleary, M., Sitharthan, T., & Hunt, G. E. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.031 · Cited by 941

Show all 42 references

Research works printed but not linked: 103

10.1159/000468273 · DOI
American Psychiatric Association, 1994, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders
10.1176/appi.books.9780890425596 · DOI · Paper page
10.1001/jama.295.17.2003 · DOI · Paper page
10.3389/fpsyt.2018.00136 · DOI
10.1002/dta.1383 · DOI · Paper page
10.1300/J160v07n04_02 · DOI
10.1002/dta.1376 · DOI
10.1111/j.1530-0277.1995.tb01554.x · DOI
10.1007/s00213-017-4777-4 · DOI
10.1097/00005053-197002000-00003 · DOI
10.1111/j.1530-0277.2007.00403.x · DOI
10.1001/archinte.158.16.1789 · DOI · Paper page
10.1093/alcalc/agh156 · DOI
10.1111/j.1360-0443.2004.00763.x · DOI
10.15288/jsa.1993.54.297 · DOI
10.3389/fphar.2018.00561 · DOI
Center for Behavioral Health Statistics and Quality, 2017, 2016 National Survey on Drug Use and Health: Detailed Tables
10.1111/add.13477 · DOI
10.1016/B978-0-12-801284-0.00001-4 · DOI
10.1016/j.drugalcdep.2018.03.044 · DOI
10.1111/j.1360-0443.2004.00964.x · DOI · Paper page
Doblin R, 1991, J Transpers Psychol, 23, 1
10.1016/j.jep.2007.04.012 · DOI
10.1590/1516-4446-2015-1701 · DOI
10.1046/j.1360-0443.2002.00252.x · DOI
10.1093/shm/hkl039 · DOI
10.2174/1874473708666150107121331 · DOI · Paper page
10.1097/NMD.0000000000000113 · DOI · Paper page
Godinho AF, 2017, Electr J Biol, 13, 159
10.1097/00008877-199811000-00011 · DOI
10.1177/0269881108094300 · DOI · Paper page
Halpern JH, 2008, Med Sci Monit, 14, SR15
10.1177/0269881114565653 · DOI
10.1016/0006-3223(92)90059-9 · DOI
10.1055/s-2007-979352 · DOI · Paper page
10.17730/humo.49.3.m70273175tn234r1 · DOI
10.1176/ajp.125.10.1352 · DOI
10.5213/inj.1632604.302 · DOI
10.1016/0010-440X(93)90061-8 · DOI
IBM Corporation, 2016, IBM SPSS Statistics for Windows
10.1177/0269881116684335 · DOI
10.1177/0269881108093587 · DOI · Paper page
Johnston LD, O’Malley PM, Bachman JG, et al. (2016) Monitoring the Future National Survey Results on Drug Use, 1975–2015: Volume II, College Students and Adults Ages. Ann Arbor: MI: Institute for Social Research, pp. 19–55.
10.1111/j.1530-0277.2011.01523.x · DOI · Paper page
10.1111/j.1530-0277.2010.01362.x · DOI
10.1016/j.pnpbp.2015.06.008 · DOI · Paper page
10.1016/j.biopsych.2012.04.005 · DOI · Paper page
10.1016/j.biopsych.2014.04.010 · DOI · Paper page
10.1176/ajp.123.10.1202 · DOI
Lattin D, 2012, Distilled Spirits: Getting High, Then Sober, with a Famous Writer, a Forgotten Philosopher, and a Hopeless Drunk, 10.1525/9780520352629 · DOI
10.1176/ajp.126.1.59 · DOI
10.1177/0269881111420188 · DOI · Paper page
10.1111/j.1468-5906.2012.01685.x · DOI · Paper page
10.1111/j.1360-0443.2012.04054.x · DOI · Paper page
10.1177/0269881114568040 · DOI
10.1080/02791072.1998.10399714 · DOI
10.1177/070674371205700604 · DOI
10.1046/j.1360-0443.1998.9379793.x · DOI
10.1002/jclp.20000 · DOI
Miller WR, 2001, Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives
10.15288/jsa.2001.62.211 · DOI · Paper page
Moyer VA, 2013, Ann Int Med, 159, 210
10.1038/tp.2017.54 · DOI
Muthén LK, 1998, Mplus User’s Guide: Statistical Analysis with Latent Variables
10.1002/cpt.557 · DOI
10.3389/fphar.2018.00132 · DOI
10.1038/nrn3530 · DOI
Osmond H, 1967, The Use of LSD in Psychotherapy and Alcoholism, 434
10.2190/PM.38.4.a · DOI
10.1080/15313204.2013.843138 · DOI
10.1111/j.1530-0277.2002.tb02534.x · DOI · Paper page
10.3389/fphar.2017.00974 · DOI · Paper page
Ross S, 2012, Psychiatr Clin, 35, 357
10.1177/0269881116675512 · DOI · Paper page
10.1016/0306-4603(94)00072-7 · DOI
10.1111/acer.13522 · DOI
10.1111/j.1465-3362.2010.00217.x · DOI · Paper page
10.1001/archpsyc.1973.01750360040005 · DOI · Paper page
10.1007/s00213-017-4733-3 · DOI · Paper page
10.1002/cpt.776 · DOI
10.1016/j.neuropharm.2017.11.004 · DOI
10.1192/bjp.bp.114.148031 · DOI
Smart RG, 1966, Quart J Stud Alcohol, 27, 469, 10.15288/qjsa.1966.27.469 · DOI
Smith CM, 1958, Quart J Stud Alcohol, 19, 406, 10.15288/qjsa.1958.19.406 · DOI
Smith CM, 1959, Quart J Stud Alcohol, 20, 292, 10.15288/qjsa.1959.20.292 · DOI
10.1016/0006-3223(95)00418-1 · DOI
10.5888/pcd11.130293 · DOI
10.1001/archpsyc.1994.03950020009001 · DOI
10.1001/archpsyc.1994.03950020022002 · DOI · Paper page
10.1007/s00213-017-4754-y · DOI
Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA), 2015, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide
10.1002/hbm.22562 · DOI
Tomsovic M, 1970, Quart J Stud Alcohol, 31, 932, 10.15288/qjsa.1970.31.932 · DOI
10.1503/cmaj.141124 · DOI · Paper page
10.1007/s00213-018-4988-3 · DOI · Paper page
10.1046/j.1360-0443.2003.00422.x · DOI · Paper page
10.1111/ejn.13572 · DOI
10.1093/alcalc/agl016 · DOI · Paper page
10.1016/S0893-133X(96)00246-1 · DOI · Paper page
10.15288/jsad.2008.69.878 · DOI
10.1177/0269881113513852 · DOI
World Health Organization (WHO), 2018, Management of Substance Abuse Unit: Global Status Report on Alcohol and Health, 2018

Sorted by citations

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citation
The subjective effects of psychedelics are necessary for their enduring therapeutic effects
Yaden, D. B., & Griffiths, R. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00194 · Cited by 541
Self-citation
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
Self-citation
Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169
Self-citation
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211066709 · Cited by 141
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00018 · Cited by 124
Self-citation
Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation
Zeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being.
Kiraga, M. K., Mason, N. L., Uthaug, M. V., van Oorsouw, K. I. M., Toennes, S. W., Ramaekers, J. G., & Kuypers, K. P. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721537 · Cited by 85
The therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review
Romeo, B., Hermand, M., Pétillion, A., Karila, L., & Benyamina, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.002 · Cited by 76
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color
Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T. (2021) · Chronic Stress · doi:10.1177/24705470211035607 · Cited by 67
Self-citation
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics
Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33
“This is true in the treatment of people with alcohol use disorder (Bogenschutz et al., 2015; Garcia-Romeu et al., 2019) and depression and anxiety (Davis et al., 2020; Griffiths et al., 2016; Roseman et al., 2018; Ross et al., 2016), as well as for success with smoking cessation (Garcia-Romeu et…”
Background
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
Lancelotta, R. L., & Davis, A. K. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1737763 · Cited by 33
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey
Buot, A., Pallares, C., Oganesyan, A., Dauré, C., Bonnelle, V., Burguière, E., Dos Santos, J. F. A., N’Diaye, K., Ljuslin, M., Smith, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39812-0 · Cited by 28
Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans
Mangini, P., Averill, L. A., & Davis, A. K. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00176 · Cited by 19
Self-citation
Do psychedelics facilitate emergence of unconscious psychological processes
Lindegaard, T. (2023) · Psychodynamic Psychiatry · doi:10.1521/pdps.2023.51.3.270 · Cited by 18

Authors: Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W.
Affiliations: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Erowid Center, Grass Valley, CA, USA
ORCID: Garcia-Romeu, Albert
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2019-05-14
Volume: 33
Issue: 9
Pages: 1088-1101
ISSN: 0269-8811
1461-7285
DOI: 10.1177/0269881119845793
Cited by: 225
References: 42
Language: en
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Funders: national institute on drug abuse (T32DA07209, R01DA003889)
heffter research institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks